Sanofi says good results from flu vaccine with mRNA booster study

[October 07, 2021]  PARIS (Reuters) - French healthcare company Sanofi said on Wednesday that it had found positive results from the first study into a high-dose influenza vaccine with a COVID-19 mRNA booster.

Sanofi said the interim results from the study of Sanofi's Fluzone High-Dose Quadrivalent vaccine with Moderna's COVID-19 mRNA investigational booster dose showed the vaccines had similar immunogenicity responses and a similar safety and tolerability profile.

"These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population," said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.

(Reporting by Sudip Kar-Gupta; Editing by Christian Schmollinger)

[© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content